Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Pneumococcal Vaccines | 4 | 2019 | 571 | 1.18 | Why? |
| Pneumococcal Infections | 4 | 2019 | 562 | 1.13 | Why? |
| Streptococcal Vaccines | 2 | 2017 | 31 | 0.89 | Why? |
| Pneumonia, Pneumococcal | 3 | 2019 | 251 | 0.85 | Why? |
| Streptococcus agalactiae | 2 | 2017 | 194 | 0.79 | Why? |
| Diphtheria-Tetanus Vaccine | 1 | 2018 | 16 | 0.77 | Why? |
| Tetanus | 1 | 2018 | 61 | 0.73 | Why? |
| Diphtheria | 1 | 2018 | 74 | 0.71 | Why? |
| Republic of Korea | 21 | 2021 | 5858 | 0.71 | Why? |
| Streptococcal Infections | 2 | 2017 | 255 | 0.67 | Why? |
| Phagocytosis | 2 | 2017 | 409 | 0.63 | Why? |
| Antibodies, Bacterial | 3 | 2018 | 510 | 0.59 | Why? |
| Influenza A Virus, H7N9 Subtype | 1 | 2018 | 415 | 0.50 | Why? |
| Vaccines, Conjugate | 3 | 2019 | 328 | 0.46 | Why? |
| Influenza, Human | 10 | 2020 | 10779 | 0.40 | Why? |
| Delayed Diagnosis | 1 | 2020 | 1529 | 0.40 | Why? |
| Vaccination | 9 | 2021 | 19050 | 0.38 | Why? |
| Cost-Benefit Analysis | 3 | 2018 | 2259 | 0.37 | Why? |
| Public Policy | 1 | 2020 | 1894 | 0.35 | Why? |
| Influenza A Virus, H3N2 Subtype | 4 | 2019 | 572 | 0.31 | Why? |
| Immunogenicity, Vaccine | 2 | 2018 | 4624 | 0.31 | Why? |
| Community-Acquired Infections | 1 | 2018 | 2328 | 0.29 | Why? |
| Herpes Zoster | 1 | 2010 | 331 | 0.28 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2010 | 952 | 0.27 | Why? |
| Pneumonia | 2 | 2019 | 5652 | 0.23 | Why? |
| Opsonin Proteins | 2 | 2017 | 18 | 0.23 | Why? |
| Influenza Vaccines | 4 | 2019 | 2941 | 0.23 | Why? |
| Asymptomatic Infections | 2 | 2020 | 7218 | 0.23 | Why? |
| Seoul | 1 | 2020 | 206 | 0.20 | Why? |
| Arthralgia | 1 | 2021 | 173 | 0.20 | Why? |
| Bartonella Infections | 1 | 2018 | 18 | 0.19 | Why? |
| Streptococcus pneumoniae | 3 | 2019 | 827 | 0.19 | Why? |
| Nasopharyngeal Neoplasms | 1 | 2019 | 64 | 0.19 | Why? |
| Cyclopentanes | 1 | 2018 | 55 | 0.19 | Why? |
| Human Activities | 1 | 2020 | 293 | 0.18 | Why? |
| Retinal Artery Occlusion | 1 | 2018 | 57 | 0.18 | Why? |
| Quality-Adjusted Life Years | 2 | 2018 | 511 | 0.17 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 9335 | 0.17 | Why? |
| Immunity, Heterologous | 1 | 2017 | 129 | 0.17 | Why? |
| Anti-HIV Agents | 1 | 2010 | 2209 | 0.17 | Why? |
| Encephalitis Viruses, Tick-Borne | 1 | 2017 | 100 | 0.16 | Why? |
| Adenovirus Infections, Human | 1 | 2018 | 145 | 0.16 | Why? |
| Communicable Disease Control | 3 | 2020 | 29620 | 0.16 | Why? |
| Meningitis, Bacterial | 1 | 2017 | 111 | 0.16 | Why? |
| Delphi Technique | 1 | 2021 | 1257 | 0.16 | Why? |
| Adenoviruses, Human | 1 | 2018 | 195 | 0.16 | Why? |
| Encephalitis, Tick-Borne | 1 | 2017 | 86 | 0.16 | Why? |
| Hemagglutinins | 1 | 2017 | 143 | 0.16 | Why? |
| Disease Outbreaks | 3 | 2020 | 27595 | 0.15 | Why? |
| Adult | 20 | 2021 | 244371 | 0.15 | Why? |
| Myalgia | 1 | 2021 | 1015 | 0.15 | Why? |
| Cross Protection | 1 | 2017 | 373 | 0.15 | Why? |
| Colonic Neoplasms | 1 | 2019 | 295 | 0.14 | Why? |
| Severe Dengue | 1 | 2017 | 135 | 0.14 | Why? |
| Aged | 17 | 2021 | 215776 | 0.14 | Why? |
| Markov Chains | 1 | 2017 | 502 | 0.14 | Why? |
| Neuraminidase | 1 | 2017 | 289 | 0.14 | Why? |
| Vaccines, Inactivated | 2 | 2019 | 1562 | 0.14 | Why? |
| Middle Aged | 17 | 2021 | 270681 | 0.14 | Why? |
| Hemagglutination Inhibition Tests | 3 | 2019 | 191 | 0.13 | Why? |
| Complement System Proteins | 1 | 2017 | 380 | 0.13 | Why? |
| Guanidines | 1 | 2018 | 499 | 0.13 | Why? |
| Female | 22 | 2021 | 380317 | 0.13 | Why? |
| Male | 19 | 2021 | 367725 | 0.12 | Why? |
| Young Adult | 10 | 2021 | 93724 | 0.12 | Why? |
| Antineoplastic Agents, Immunological | 1 | 2019 | 830 | 0.11 | Why? |
| Pneumonia, Bacterial | 1 | 2019 | 843 | 0.11 | Why? |
| Healthy Volunteers | 1 | 2017 | 1444 | 0.11 | Why? |
| Immunization Programs | 3 | 2019 | 2006 | 0.11 | Why? |
| Health Personnel | 2 | 2021 | 29646 | 0.11 | Why? |
| Fever | 2 | 2019 | 7795 | 0.11 | Why? |
| Humans | 32 | 2021 | 930598 | 0.11 | Why? |
| Incidence | 3 | 2020 | 25622 | 0.11 | Why? |
| Resource Allocation | 1 | 2021 | 1771 | 0.10 | Why? |
| Health Communication | 1 | 2020 | 1120 | 0.10 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.10 | Why? |
| HIV Infections | 2 | 2018 | 11620 | 0.10 | Why? |
| Health Care Costs | 1 | 2017 | 1007 | 0.09 | Why? |
| Lymphohistiocytosis, Hemophagocytic | 1 | 2017 | 800 | 0.09 | Why? |
| Military Personnel | 1 | 2018 | 1097 | 0.09 | Why? |
| Hospitals, University | 1 | 2020 | 4173 | 0.09 | Why? |
| Antibodies, Viral | 1 | 2020 | 51949 | 0.09 | Why? |
| Aged, 80 and over | 6 | 2020 | 88759 | 0.09 | Why? |
| Coronavirus Infections | 6 | 2021 | 253789 | 0.08 | Why? |
| Outpatients | 1 | 2020 | 3417 | 0.08 | Why? |
| Influenza A Virus, H1N1 Subtype | 2 | 2019 | 2984 | 0.08 | Why? |
| Serogroup | 2 | 2019 | 510 | 0.08 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.08 | Why? |
| Vulnerable Populations | 1 | 2020 | 3099 | 0.07 | Why? |
| Dyspnea | 1 | 2019 | 3847 | 0.07 | Why? |
| Cough | 1 | 2019 | 4891 | 0.07 | Why? |
| Schools | 1 | 2020 | 4187 | 0.07 | Why? |
| Hospitals, Teaching | 1 | 2013 | 1609 | 0.07 | Why? |
| Epidemiological Monitoring | 1 | 2018 | 3493 | 0.07 | Why? |
| Seroepidemiologic Studies | 1 | 2020 | 10017 | 0.07 | Why? |
| Saliva | 1 | 2020 | 4679 | 0.06 | Why? |
| Evolution, Molecular | 1 | 2017 | 3691 | 0.06 | Why? |
| Infant | 3 | 2021 | 30274 | 0.06 | Why? |
| HIV | 1 | 2010 | 1116 | 0.06 | Why? |
| Health Behavior | 1 | 2020 | 4449 | 0.06 | Why? |
| Infant, Newborn | 2 | 2021 | 23105 | 0.06 | Why? |
| Child, Preschool | 3 | 2021 | 36283 | 0.06 | Why? |
| Immunoassay | 1 | 2017 | 4485 | 0.06 | Why? |
| Breast Neoplasms | 1 | 2019 | 3633 | 0.05 | Why? |
| Joints | 1 | 2021 | 97 | 0.05 | Why? |
| Seasons | 3 | 2018 | 4071 | 0.05 | Why? |
| Bartonella | 1 | 2018 | 24 | 0.05 | Why? |
| Viral Load | 1 | 2020 | 15850 | 0.05 | Why? |
| Acids, Carbocyclic | 1 | 2018 | 27 | 0.05 | Why? |
| Travel | 1 | 2018 | 7220 | 0.05 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2021 | 8843 | 0.05 | Why? |
| Economics, Pharmaceutical | 1 | 2018 | 61 | 0.05 | Why? |
| Blood Bactericidal Activity | 1 | 2017 | 19 | 0.05 | Why? |
| Phylogeny | 4 | 2018 | 13341 | 0.05 | Why? |
| Surveys and Questionnaires | 3 | 2021 | 43792 | 0.05 | Why? |
| Lymphadenitis | 1 | 2018 | 53 | 0.05 | Why? |
| Public Health | 2 | 2021 | 16359 | 0.04 | Why? |
| Respiratory Tract Infections | 1 | 2018 | 6817 | 0.04 | Why? |
| Molecular Typing | 1 | 2018 | 280 | 0.04 | Why? |
| Rifampin | 1 | 2018 | 276 | 0.04 | Why? |
| Cost Savings | 1 | 2018 | 296 | 0.04 | Why? |
| Marketing | 1 | 2018 | 195 | 0.04 | Why? |
| Population Surveillance | 1 | 2013 | 4967 | 0.04 | Why? |
| Tomography, X-Ray Computed | 2 | 2021 | 25144 | 0.04 | Why? |
| RNA, Viral | 3 | 2018 | 32276 | 0.04 | Why? |
| Virus Diseases | 1 | 2013 | 3779 | 0.04 | Why? |
| Adolescent | 3 | 2021 | 86841 | 0.04 | Why? |
| Single-Blind Method | 1 | 2019 | 1283 | 0.04 | Why? |
| Fluorescein Angiography | 1 | 2018 | 426 | 0.04 | Why? |
| Pandemics | 7 | 2021 | 389249 | 0.04 | Why? |
| Antigens, Bacterial | 1 | 2017 | 330 | 0.04 | Why? |
| Child | 2 | 2021 | 70012 | 0.03 | Why? |
| Influenza B virus | 1 | 2019 | 815 | 0.03 | Why? |
| Cross-Sectional Studies | 1 | 2020 | 53120 | 0.03 | Why? |
| Antipsychotic Agents | 1 | 2021 | 887 | 0.03 | Why? |
| Molecular Epidemiology | 1 | 2018 | 1638 | 0.03 | Why? |
| Ageism | 1 | 2018 | 361 | 0.03 | Why? |
| Visual Acuity | 1 | 2018 | 790 | 0.03 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2018 | 533 | 0.03 | Why? |
| Lymph Nodes | 1 | 2018 | 1060 | 0.03 | Why? |
| Vaccines, Subunit | 1 | 2017 | 1088 | 0.03 | Why? |
| Cohort Studies | 2 | 2018 | 36005 | 0.03 | Why? |
| Meta-Analysis as Topic | 1 | 2017 | 1289 | 0.03 | Why? |
| Sentinel Surveillance | 1 | 2017 | 1093 | 0.02 | Why? |
| Mice | 2 | 2017 | 21357 | 0.02 | Why? |
| Early Diagnosis | 1 | 2017 | 2443 | 0.02 | Why? |
| Age Factors | 2 | 2018 | 21039 | 0.02 | Why? |
| Retrospective Studies | 1 | 2018 | 105322 | 0.02 | Why? |
| Decision Making | 1 | 2021 | 3132 | 0.02 | Why? |
| Cost of Illness | 1 | 2017 | 1903 | 0.02 | Why? |
| Odds Ratio | 1 | 2018 | 5861 | 0.02 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.02 | Why? |
| Risk | 1 | 2017 | 5288 | 0.02 | Why? |
| Antiviral Agents | 1 | 2018 | 41703 | 0.02 | Why? |
| Multiplex Polymerase Chain Reaction | 1 | 2013 | 1439 | 0.02 | Why? |
| Vaccines, Synthetic | 1 | 2017 | 3231 | 0.02 | Why? |
| Japan | 1 | 2017 | 6653 | 0.02 | Why? |
| Polymerase Chain Reaction | 1 | 2018 | 6740 | 0.02 | Why? |
| Prospective Studies | 2 | 2018 | 43301 | 0.02 | Why? |
| Chronic Disease | 1 | 2017 | 5139 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2017 | 7220 | 0.01 | Why? |
| Research Design | 1 | 2018 | 5830 | 0.01 | Why? |
| Sex Factors | 1 | 2018 | 11014 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2021 | 11041 | 0.01 | Why? |
| Case-Control Studies | 1 | 2019 | 17671 | 0.01 | Why? |
| Antigens, Viral | 1 | 2017 | 6298 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.01 | Why? |
| Adrenal Cortex Hormones | 1 | 2017 | 6537 | 0.01 | Why? |
| Animals | 2 | 2017 | 78931 | 0.01 | Why? |
| Anticoagulants | 1 | 2018 | 9563 | 0.01 | Why? |
| Hospitalization | 2 | 2018 | 54280 | 0.01 | Why? |
| Anti-Bacterial Agents | 1 | 2018 | 10083 | 0.01 | Why? |
| Viral Vaccines | 1 | 2017 | 7560 | 0.01 | Why? |
| Time Factors | 1 | 2018 | 31397 | 0.01 | Why? |
| Treatment Outcome | 1 | 2021 | 51732 | 0.01 | Why? |
| Hospital Mortality | 1 | 2017 | 22087 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| China | 1 | 2017 | 50654 | 0.01 | Why? |
| Risk Factors | 1 | 2018 | 71621 | 0.01 | Why? |
Song's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(179)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(80)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_